AVTX (Avalo Therapeutics) Shiller PE Ratio: (As of Sep. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVTX Avalo Therapeutics Inc AVTX
26 GF Score
Price $16.69
GF Value $0.20
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Avalo Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Avalo Therapeutics  (NAS:AVTX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Avalo Therapeutics Shiller PE Ratio Related Terms


Avalo Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Avalo Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalo Therapeutics Shiller PE Ratio Chart

Avalo Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Avalo Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AVTX vs SLDB, SLNCF, OBX: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Avalo Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avalo Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Avalo Therapeutics's Shiller PE Ratio falls into.


AVTX
26GF Score
Avalo Therapeutics Inc AVTX
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalo Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Avalo Therapeutics's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Avalo Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.8339/333.9520*333.9520
=-0.834

Current CPI (Jun. 2026) = 333.9520.

Avalo Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201606 -1,180.800 241.018 -1,636.104
201609 -2,016.000 241.428 -2,788.605
201612 -518.400 241.432 -717.058
201703 -547.200 243.801 -749.540
201706 -403.200 244.955 -549.691
201709 1,497.600 246.819 2,026.289
201712 -725.386 246.524 -982.638
201803 -357.091 249.554 -477.858
201806 -536.573 251.989 -711.101
201809 -2,045.059 252.439 -2,705.412
201812 -509.674 251.233 -677.485
201903 -427.421 254.202 -561.514
201906 -375.898 256.143 -490.085
201909 -219.024 256.759 -284.872
202003 -970.070 258.115 -1,255.088
202006 -555.494 257.797 -719.591
202009 -478.022 260.280 -613.326
202012 -554.054 260.474 -710.349
202103 -931.651 264.877 -1,174.609
202106 -506.707 271.696 -622.813
202109 -498.528 274.310 -606.921
202112 -492.422 278.802 -589.829
202203 -563.040 287.504 -654.002
202206 -331.546 296.311 -373.663
202209 81.379 296.808 91.563
202212 -249.965 296.797 -281.257
202303 -203.808 301.836 -225.494
202306 -140.734 305.109 -154.038
202309 -26.832 307.789 -29.113
202312 -10.188 306.746 -11.091
202403 -141.137 312.332 -150.906
202406 -14.071 314.175 -14.957
202409 -2.834 315.301 -3.002
202412 -3.375 315.605 -3.571
202503 -1.251 319.799 -1.306
202506 -1.917 322.561 -1.985
202509 -2.187 324.800 -2.249
202512 -0.741 324.054 -0.764
202603 -0.976 330.213 -0.987
202606 -0.834 333.952 -0.834

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Avalo Therapeutics (AVTX) Overvalued in 2026?

Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued. The current stock price of $16.69 is trading 8245% above its estimated GF Value™ of $0.20. GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.

Key valuation signals for AVTX:

  • Shiller PE Ratio:
  • GF Value™: $0.20 vs. price of $16.69 (8245% above fair value)
  • GF Score™: 26/100 with 5 warning signs

No single metric tells the full story. See the AVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Avalo Therapeutics Business Description

Other Exchanges C6K0:Germany
Address 1500 Liberty Ridge Drive, Suite 321, Wayne, PA, USA, 19087
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
26GF Score

Get the complete analysis for AVTX

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.69
Price
$0.20
GF Value